Search

United Therapeutics Corp

Deschisă

SectorSănătate

516.17 -1.6

Rezumat

Modificarea prețului

24h

Curent

Minim

508.46

Maxim

530.88

Indicatori cheie

By Trading Economics

Venit

58M

333M

Vânzări

1.8M

783M

P/E

Medie Sector

18.206

57.366

EPS

7.27

Marjă de profit

42.512

Angajați

1,400

EBITDA

32M

376M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+26.8% upside

Dividende

By Acuity

Următoarele câștiguri

28 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-3.9B

22B

Deschiderea anterioară

517.77

Închiderea anterioară

516.17

Sentimentul știrilor

By Acuity

31%

69%

99 / 340 Clasament în Healthcare

United Therapeutics Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 aug. 2026, 19:46 UTC

News

United Therapeutics shares are lower as CEO Martine Rothblatt exercised an option for 9,500 shares at $135.42, raising potential supply concerns.

25 aug. 2026, 23:26 UTC

United Therapeutics Corp. shares are trading roughly flat in after-market hours, reflecting routine performance and remaining near the middle of their one-month trading range.

24 aug. 2026, 21:01 UTC

Event

United Therapeutics shares lower in after-market hours following FDA acceptance of ralinepag's New Drug Application for pulmonary arterial hypertension.

21 aug. 2026, 19:46 UTC

News

United Therapeutics Corp shares are lower amid rising U.S. Treasury yields, which have heightened concerns about inflation and government debt levels.

20 aug. 2026, 23:16 UTC

Shares of United Therapeutics Corp are trading higher in after-market hours, despite routine fluctuations and a decrease from an earlier high.

19 aug. 2026, 22:02 UTC

United Therapeutics Corp. shares declined in after-market trading, reversing gains from the previous three sessions. No specific news was identified to explain the drop.

18 aug. 2026, 19:11 UTC

Event
News

United Therapeutics shares are higher, supported by insider activity and full enrollment in the TETON-PPF study evaluating Tyvaso for pulmonary fibrosis.

17 aug. 2026, 19:46 UTC

News
Social Media
Event

United Therapeutics Corp completed enrollment in its Phase 3 TETON-PPF study for Tyvaso, and shares are advancing during Monday's session, despite a pullback earlier.

13 aug. 2026, 19:51 UTC

United Therapeutics Corp shares are lower today, breaking a trend of higher closes. No specific news was identified to explain the decline.

12 aug. 2026, 23:01 UTC

United Therapeutics Corp shares are higher in after-market trading, supported by easing concerns over Federal Reserve rate hikes amid rising consumer prices.

11 aug. 2026, 23:02 UTC

United Therapeutics Corp is trading lower in after-market hours, continuing a trend of three consecutive daily declines without any specific news driving the movement.

10 aug. 2026, 20:06 UTC

United Therapeutics Corp shares are lower during Monday's session, with no specific news identified to explain the decline amid broader market volatility.

7 aug. 2026, 19:51 UTC

Social Media
News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

6 aug. 2026, 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

5 aug. 2026, 20:02 UTC

News
Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

4 aug. 2026, 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

3 aug. 2026, 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

30 iul. 2026, 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

29 iul. 2026, 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

28 iul. 2026, 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

24 iul. 2026, 16:36 UTC

News
Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

22 iul. 2026, 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

21 iul. 2026, 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Comparație

Modificare preț

United Therapeutics Corp Așteptări

Obiectiv de preț

By TipRanks

26.8% sus

Prognoză pe 12 luni

Medie 655.13 USD  26.8%

Maxim 714 USD

Minim 515 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUnited Therapeutics Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

7

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

99 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat